

Your reference
Our reference
Date

May 22, 2024

Changes to Columbia Threadneedle (Lux) I (“CT”) and the Underlying Funds (as defined below)

Zurich Assurance Ltd
(a company incorporated
in England and Wales
with limited liability)

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

We accept full responsibility for the accuracy of the content of this document. For any capitalized terms that are not specifically defined in this letter, please refer to the definition in the Hong Kong offering documents of CT.

**Zurich Life Insurance
(Hong Kong) Limited**
(a company incorporated in
Hong Kong with limited liability)

Dear valued customer,

25-26/F, One Island East
18 Westlands Road
Island East, Hong Kong

We are writing to let you know about the changes to CT and the Underlying Funds. You have invested in at least one of the investment choices corresponding to the Underlying Funds, which are listed in the “Which investment choices are affected?” table below under the column “Name and code of the investment choice”.

Website: www.zurich.com.hk

Which investment choices are affected?

Name and code of the investment choice (Individually, the “Investment Choice”; collectively, the “Investment Choices”)	Name of the corresponding underlying fund (Individually, the “Underlying Fund”; collectively, the “Underlying Funds”)	Applicable scheme (Collectively, the “Schemes”)
Columbia Threadneedle (Lux) I - CT (Lux) Asian Equity Income (Code: OVUSD)	Columbia Threadneedle (Lux) I - CT (Lux) Asian Equity Income	<ul style="list-style-type: none"> • Magnitude • Matterhorn • Swiss Elite
Columbia Threadneedle (Lux) I - CT (Lux) Global Focus (Code: OWUSD)	Columbia Threadneedle (Lux) I - CT (Lux) Global Focus	

What is happening?

We have been notified by the Board of CT of (1) changes to the provision of pre-contractual information pursuant to Article 8 or 9 of the Sustainable Finance Disclosure Regulation (the “**SFDR**”) and (2) certain changes to CT and the Underlying Funds.

These changes will not affect the way the Underlying Funds are managed nor change the risk profile of the Underlying Funds.

1. Availability of pre-contractual information pursuant to SFDR

The annexes which contain the pre-contractual information pursuant to the SFDR regulatory technical standard in respect of the Underlying Funds that fall within the scope of Article 8 or 9 of the SFDR (the “**Annexes**”) will no longer form part of the Hong Kong offering documents. The Annexes in respect of the Article 8 or 9 Underlying Funds which are authorized by the SFC will be available to Hong Kong investors (in English language only) free of charge on the website www.columbiathreadneedle.com¹ and will not be appended to the Prospectus distributed in Hong Kong.

2. Other enhancements and miscellaneous updates

The Hong Kong offering documents of CT have also been updated to reflect other enhancement of disclosures and miscellaneous updates, including but not limited to:

- Updates to the list of directors of CT, list of directors and conducting persons of the Management Company, and address of the Registrar and Transfer Agent;
- Editorial updates to the language regarding each Underlying Fund’s ancillary liquid assets and streamlining of disclosures regarding each Underlying Fund’s deviation from its relevant index;
- Enhancements of disclosures to include additional risk factors in respect of market risk, the Russia-Ukraine conflict, inflation, investment style, and ESG investment exclusions, as well as streamlining of obsolete risk disclosures;
- Update to reflect that dealings in Shares shall be forbidden where CT does not have a depositary, or in cases where CT declares bankruptcy, applies for a scheme of composition with creditors (*bénéfice de concordat*), suspension of payments (*sursis de paiement*) or controlled management (*gestion contrôlée*), or upon occurrence of any such event affecting the Depositary;
- Update to reflect additional obligation of Depositary to take all measures necessary for proper preservation of the interests of the investors;
- ESG-related updates and enhancement of disclosures; and
- Editorial updates to disclosures on the investment advisory arrangements applicable to the Underlying Funds.

Please refer to the Hong Kong offering documents of CT for further details.

The current Hong Kong offering documents of CT, the articles of association of CT and the most recent annual and semi-annual reports are available on the website www.columbiathreadneedle.com¹. The updated versions of the articles of association and the Hong Kong offering documents of CT which will reflect the changes detailed above will be also available in the same manner in due course.

¹ Please note that this website has not been reviewed by the SFC. The website is not specifically directed to Hong Kong residents and may contain information with respect to non-SFC authorized funds of CT which are not available for public offer in Hong Kong.

What does this mean to you?

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 2968 2383 or contact us via <https://www.zurich.com.hk/zh-hk/customer-services/contact-us/e-form/life-general> and we will be happy to help.

Yours faithfully,

Zurich Life Insurance (Hong Kong) Limited
(a company incorporated in Hong Kong with limited liability)

Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.

有關天利（盧森堡）（「CT」）及該等相關基金（定義見下文）之變更

蘇黎世人壽
 （於英格蘭及威爾斯註冊
 成立之有限公司）

蘇黎世人壽保險（香港）有限公司
 （於香港註冊成立之有限公司）

香港港島東華蘭路18號
 港島東中心25-26樓

網址: www.zurich.com.hk

此乃重要函件，務請您即時垂注。您如對本函件的內容有任何疑問，請尋求專業意見。

我們就此函件所轉載資料的準確性承擔全部責任。除非另有訂明，否則本函件所載詞彙應與CT的香港銷售文件所載者具有相同涵義。

親愛的客戶：

我們謹此致函通知您有關CT及該等相關基金的變更。您已投資於該等相關基金相應的至少一個投資選項，其列於下表「受影響的投資選項」中「投資選項的名稱及代碼」一欄。

受影響的投資選項

投資選項的名稱及代碼 (各稱為「該投資選項」，統稱為「該等投資選項」)	相應的相關基金名稱 (各稱為「該相關基金」，統稱為「該等相關基金」)	適用計劃 (統稱「計劃」)
天利（盧森堡）- 亞洲股票收入基金（代碼：OVUSD）	天利（盧森堡）- 亞洲股票收入基金	<ul style="list-style-type: none"> 瑞豐投資計劃 瑞承投資計劃 瑞翔投資計劃
天利（盧森堡）- 全球焦點基金（代碼：OWUSD）	天利（盧森堡）- 全球焦點基金	

修訂事項

CT的董事會已通知我們 (1) 對於根據可持續金融披露規例（「SFDR」）第8條或第9條提供的訂約前資料的更改及 (2) CT及該等相關基金的若干更改。

此等更改不會影響該等相關基金的管理方式或改變該等相關基金的風險概況。

1. 根據SFDR可提供的訂約前資料

載有根據SFDR監管技術標準就屬於SFDR第8條或第9條範圍內的該等相關基金提供的訂約前資訊之附件（「附件」）將不再為香港銷售文件的一部分。有關獲證監會認可的第8條及第9條該等相關基金的附件（僅備有英文版）將可供香港投資者從網站 www.columbiathreadneedle.com¹免費索取，並且不附於在香港派發的說明書。

2. 其他加強披露及雜項更新

CT的香港銷售文件亦已作出更新，以反映其他加強披露及雜項更新，包括但不限於：

- 更新CT董事的名單、管理公司董事和執行人員的名單，以及註冊處與過戶代理人的地址；
- 對有關每一該相關基金的輔助性流動資產的措辭作出編輯上的更新及簡化有關每一該相關基金與其相關指數的偏差之披露；
- 加強披露以納入有關市場風險、俄羅斯-烏克蘭衝突、通脹、投資風格及ESG投資排除的新增風險因素，以及簡化過時的風險披露；
- 更新，以反映倘若CT並無存管人，或倘若CT宣佈破產、申請與債權人達成和解方案 (*bénéfice de concordat*)、暫停付款 (*sursis de paiement*) 或控制管理 (*gestion contrôlée*)，或發生影響存管人的任何事件，則股份交易將被禁止；
- 更新，以反映存管人採取一切必要措施妥善保護投資者的利益之新增責任；
- ESG相關更新及加強披露；及
- 對適用於該等相關基金的投資顧問協議書的披露作出編輯上的更新。

¹請注意，此網站並未經證監會審閱。該網站並非特別為香港居民而設，其可能載有並未經證監會認可且不可在香港作公開發售的CT基金之資料。

請參閱CT的香港銷售文件以了解進一步詳情。

CT現有的香港銷售文件、CT的註冊成立章程及最新的年度及半年度報告在網站www.columbiathreadneedle.com¹可供免費索取。註冊成立章程及CT香港銷售文件的已更新版本將反映上文詳載的更改，亦將在適當時候以相同形式可供索取。

對您產生的影響

如您在考慮上述變更後仍繼續投資於該等投資選項，則無需就此修訂作出任何行動。倘若您不欲繼續投資於該等投資選項，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選項的指示，費用全免。

我們建議您首先諮詢您的持牌保險中介人，以取得其他投資選項的建議。有關本公司投資選項（包括費用及收費，以及其相關風險因素）的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

如您對本函件或投資選項中的投資有任何疑問，請聯絡您的持牌保險中介人。您亦可致電+852 2968 2383或經由<https://www.zurich.com.hk/zh-hk/customer-services/contact-us/e-form/life-general>聯絡我們，我們將樂意為您效勞。

蘇黎世人壽保險（香港）有限公司
（於香港註冊成立之有限公司）
2024年5月22日

註：投資涉及風險，您的投資價值及收益可因市場及貨幣波動而下跌，有可能導致您不能取回所有投資款項。